Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group Academic Article uri icon

Overview

MeSH Major

  • Acetylmuramyl-Alanyl-Isoglutamine
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Immunologic Factors
  • Osteosarcoma
  • Phosphatidylethanolamines

abstract

  • When the metastatic cohort was considered in isolation, the addition of liposomal MTP-PE to chemotherapy did not achieve a statistically significant improvement in outcome. However, the pattern of outcome is similar to the pattern in nonmetastatic patients.

publication date

  • November 15, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2783515

Digital Object Identifier (DOI)

  • 10.1002/cncr.24566

PubMed ID

  • 19637348

Additional Document Info

start page

  • 5339

end page

  • 48

volume

  • 115

number

  • 22